Showing results (51-60 of 62) with videos related to
Sort By:
Pageof 7
Cancer Research|March 26, 2002
Circulating Tumor-reactive CD8(+) T cells in melanoma patients contain a CD45RA(+)CCR7(-) effector subset exerting ex vivo tumor-specific cytolytic activityDanila Valmori, Carmen Scheibenbogen, Valerie Dutoit, et al.Blood Advances|October 25, 2019
Molecular response with blinatumomab in relapsed/refractory B-cell precursor acute lymphoblastic leukemiaNicola Gökbuget, Hagop M Kantarjian, Monika Brüggemann, et al.Blood|May 18, 2012
Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomabMatthias Klinger, Christian Brandl, Gerhard Zugmaier, et al.Blood|January 24, 2018
Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemiaNicola Gökbuget, Hervé Dombret, Massimiliano Bonifacio, et al.Oncogene|June 2, 2018
Immune checkpoints PVR and PVRL2 are prognostic markers in AML and their blockade represents a new therapeutic optionHauke Stamm, Felix Klingler, Eva-Maria Grossjohann, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2016
Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I StudyMaria-Elisabeth Goebeler, Stefan Knop, Andreas Viardot, et al.Journal for Immunotherapy of Cancer|October 13, 2020
Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumorsAlbiruni Ra Razak, James M Cleary, Victor Moreno, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 23, 2023
Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I StudyLuis Paz-Ares, Stephane Champiat, W Victoria Lai, et al.The Lancet. Oncology|December 20, 2014
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 studyMax S Topp, Nicola Gökbuget, Anthony S Stein, et al.Blood|October 2, 2012
Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALLMax S Topp, Nicola Gökbuget, Gerhard Zugmaier, et al.Pageof 7